MJ-26
MJ-26 is an inhibitor targeting Menin. MJ-26 has high binding affinity (Ki: 0.56 μM) and significant antiproliferative activity. MJ-26 works by inhibiting Menin-MLL interaction and inducing Menin protein degradation. MJ-26 has significant antitumor effects on acute myeloid leukemia (AML) . MJ-26 can be used in AML research[1].
Product Specifications
UNSPSC
12352005
Target
Epigenetic Reader Domain
Related Pathways
Epigenetics
Field of Research
Cancer
Smiles
CC1=C(N=C(S1)N2CC=C(CC2)C3=CC4=C(N=CN=C4N3)N5CCC(O)(CC5)C)C6=CC=CC(S(=O)(N7C[C@@H]8C[C@H]7CN8C(/C=C/CN(C)C)=O)=O)=C6
Molecular Formula
C38H47N9O4S2
Molecular Weight
757.97
References & Citations
[1]Mo J, et al. Design, synthesis, and evaluation of Menin-targeting compounds for the treatment of acute Myelocytic leukemia (AML) . Eur J Med Chem. 2025 Jun 12;296:117847.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
